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Background.This study aimed to assess the relationship between diabetes, obesity, and hepatic steatosis in patients undergoing liver
resection and to determine if these factors are independent predictors of major complications.Materials andMethods. Analysis of a
prospectively maintained database of patients undergoing liver resection between 2005 and 2012 was undertaken. Background liver
was assessed for steatosis and classified as <33% and ≥33%. Major complications were defined as Grade III–V complications using
theDindo-Clavien classification.Results. 504 patients underwent liver resection, ofwhom56haddiabetes and 61 had steatosis≥33%.
Median BMI was 26 kg/m2 (16–54 kg/m2). 94 patients developed a major complication (18.7%). BMI ≥ 25 kg/m2 (𝑃 = 0.001) and
diabetes (𝑃 = 0.018) were associated with steatosis ≥33%. Only insulin dependent diabetes was a risk factor formajor complications
(𝑃 = 0.028). Age, male gender, hypoalbuminaemia, synchronous bowel procedures, extent of resection, and blood transfusion were
also independent risk factors. Conclusions. Liver surgery in the presence of steatosis, elevated BMI, and non-insulin dependent
diabetes is not associated with major complications. Although diabetes requiring insulin therapy was a significant risk factor, the
major risk factors relate to technical aspects of surgery, particularly synchronous bowel procedures.
1. Introduction
Liver failure occurs in up to 32% of patients following liver
resection [1–5] and is a major contributor to both morbidity
[6] and mortality [7]. Liver resection is technically more
difficult in patients with parenchymal liver disease [8] and the
risks of liver resection are increased due to impaired hepatic
regeneration [9].
Nonalcoholic fatty liver disease (NAFLD) is the common-
est cause of liver disease in the West [10] and is also the com-
monest cause of a sustained rise in serum transaminases in
patients with no history of chronic liver disease [11]. NAFLD
encompasses steatosis (excess accumulation of triglycerides),
steatohepatitis (hepatocyte damage, inflammatory infiltrate,
and fibrosis), and cirrhosis [12] and can be demonstratedwith
routine histological staining. NAFLD is associated with dia-
betesmellitus and obesity [13, 14] which are also undergoing a
global epidemic [15, 16].However, not all patientswith obesity
and diabetes develop NAFLD and similarly not all patients
with NAFLD suffer either diabetes or obesity [17].
Liver-directed chemotherapy is also associated with hep-
atotoxicity. Steatohepatitis has been shown to occur in 20%
of patients who receive irinotecan and 5% of those who
receive fluorouracil (5FU) [18], with a resulting increase in
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complications after surgery. Oxaliplatin is associated with
sinusoidal obstruction syndrome [18, 19]. Recreational alco-
hol use is also a major cause of hepatic steatosis [20].
A meta-analysis has shown that hepatic steatosis is
associated with increased risk of postoperative complications
and that moderate and severe steatosis are associated with
increased mortality compared to patients with normal liver
parenchyma or mild steatosis [21]. However, this analysis
is based on four studies, only two of which included both
BMI and diabetes inmultivariate analyses [8, 22–24]. Obesity,
diabetes, and hepatic steatosis often coexist in the metabolic
syndrome [25], and the increased risk of operating in the
presence of steatosis may be due to associated comorbidity.
Diabetes mellitus and obesity are independent risk factors for
postoperative complications following other types of major
surgery, including infectious [26–28], cardiovascular [28, 29],
and renal complications [26, 28, 29]. Furthermore in the
four studies included in the meta-analysis heterogeneous
definitions of postoperative complications were used, and
often relatively minor complications were included. Recently
complications after liver surgery have been classified by
the Dindo-Clavien system [30], which stratifies severity of
complications and allows comparison of outcomes between
centres.
The aim of this study was to assess the relationship
between the incidence of diabetes, obesity, and hepatic
steatosis in patients undergoing liver resection after a period
of abstention from alcohol consumption and to determine
if these factors are independent predictors of major com-
plications following liver resection, using the Dindo-Clavien
system.
2. Materials and Methods
A retrospective analysis of a prospectively maintained
database of all patients undergoing liver resection between
July 2005 and September 2012 was undertaken. Patient char-
acteristics, laboratory data, and intraoperative details were
retrieved. BMI was recorded preoperatively and the cohort
was divided into three categories: 18.5–24.99 kg/m2 (nor-
mal), 25–29.99 kg/m2 (overweight), and ≥30 kg/m2 (obese).
Diabetes was categorised according to the requirement for
insulin. The presence of preexisting chronic liver disease was
confirmed by histology. American Association of Anesthe-
siologists (ASA) grade was determined by the responsible
anaesthetist and the physiologic score calculated according
to the POSSUM system [31]. Selected patients were treated
with neoadjuvant chemotherapy. All patients underwent
preoperative counselling by a nurse specialist where absten-
tion from alcohol was mandated. This instruction was also
contained in a patient information sheet.The normal interval
from preoperative counselling to surgery in this series is
approximately 30 days.
Liver resections were defined according to the Brisbane
classification [32] and undertaken using standard techniques,
using hepatic inflow occlusion selectively. Major resections
were defined as resections of three or more segments. Syn-
chronous liver and bile-duct resections were performed in
the presence of hilar cholangiocarcinoma. Radiofrequency
ablation was used where small lesions were not accessible for
surgical resection.
Major complicationswere defined asGrade III–V compli-
cations using the Dindo-Clavien classification where Grade
III complications are those requiring surgical, endoscopic, or
radiological intervention, Grade IV includes life threatening
complications including organ failure, and Grade V is death
[30]. Posthepatectomy liver failure (PHLF) was defined in
accordance with the International Study Group of Liver
Surgery (ISGLS) [33] as an increased prothrombin time (PT)
and serum bilirubin concentration on or after postoperative
day five. In patients with preoperatively increased PT or
serum bilirubin concentration PHLF was defined as an
increasing serum bilirubin concentration and PT on or
after postoperative day 5, compared with the values of the
previous day. Renal dysfunction was defined as an increase in
serum creatinine of ≥1.5-fold from the preoperative baseline,
according to RIFLE criteria [34].
Serum biochemistry tests and coagulation assays were
performed preoperatively, in the first 24 postoperative hours,
and then repeated according to clinical course. The peak
measurement of bilirubin, prothrombin time (PT), and cre-
atinine was recorded. Clotting factors were not adminis-
tered between postoperative days (POD) 1–5. At histological
examination the background liver parenchyma at least 1 cm
from the tumour edge was assessed for degree of steatosis
using the Brunt classification (the proportion of hepatocytes
containing fat droplets; 1:<33%, 2: 33–66%, and 3:>66%) [35].
For analysis the data was divided into <33% (mild or none)
and ≥33% (moderate or severe).
The minimum postoperative followup was 90 days and
mortality was recorded along with details of postoperative
intervention and complications.
To determine potential associations between patient
characteristics and steatosis and between patient, operative,
and histological characteristics and major complications
univariate logistic regression or chi-square test at the level
of 𝑃 < 0.25 [36] was performed, as appropriate. Significant
variables in the univariate analysis were included in the
multivariate logistic regressionmodel andwere considered to
be significant if 𝑃 < 0.05. All analyses were carried out using
the statistical package R 2.1.14 [37].
3. Results
Of 504 patients treated in the study period, surgery was
undertaken for metastatic disease in 358 (71.0%), of whom
308 (61.1%) had colorectal liver metastases. Resections were
performed for primary hepatic malignancy in 106 patients
(21.0%) including hepatocellular carcinoma in 39 (7.7%) and
cholangiocarcinoma in 31 (6.2%) patients. In 40 patients
(7.9%) resection was performed for benign tumours. Major
resection was undertaken in 299 patients (59.3%). In twenty-
three patients a synchronous bowel procedurewas performed
including 10 colonic resections, 11 small bowel procedures,
one gastric resection, and one Whipple’s procedure. Fifty-
six patients were diabetic (11.1%), of whom 15 were insulin
dependent (26.8%). The median BMI of patients undergoing
resection was 26 kg/m2 (range 16–54 kg/m2). Elevated BMI
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Figure 1: Box plot of body mass index (BMI), diabetic status, and
degree of hepatic steatosis in 439 patients undergoing liver resection.
Nil versus <33% (𝑃 < 0.001), <33 versus ≥33% (𝑃 = 0.001).
(≥25 kg/m2) was noted in 332 patients (65.9%) and 123
patients (24.4%) were obese (≥30 kg/m2). Five patients had
no BMI recorded and were excluded from analysis. Preop-
erative liver-directed chemotherapy was used in 168 patients
(33.3%). The most commonly used regime was oxaliplatin
and capecitabine which was used in 118 patients (70.2%).
Irinotecan was used in six patients (3.6%).
Histopathological examination revealed zero, mild, mod-
erate, and severe steatosis in 199 (39.5%), 179 (35.5%), 54
(10.7%), and seven (1.4%) patients, respectively. Degree of
steatosis was not recorded in 65 patients (12.9%). The distri-
bution of BMI, diabetes, and steatosis is shown in Figure 1.
The median BMI of patients with no steatosis (25 kg/m2,
range 16–45) was lower than those with mild steatosis
(27 kg/m2, range 18–44) (𝑃 < 0.001), which was lower than
patients with moderate/severe steatosis (29 kg/m2, range 22–
42) (𝑃 = 0.001). The median BMI of diabetic patients
was 29 kg/m2 (16–40) compared to 26 kg/m2 (17–54) in
nondiabetic patients (𝑃 = 0.002). There was no difference in
the median BMI of patients with insulin dependent diabetes
(IDDM) (29 kg/m2, range 16–40) and those with non-insulin
dependent diabetes (NIDDM) (29 kg/m2, range 20–39) (𝑃 =
0.816). The rate of mild steatosis among diabetics was 16/52
(30.8%) compared to 45/387 (11.6%) in nondiabetics (𝑃 =
0.001), but there was no significant difference in the rates
of mild steatosis in patients with NIDDM (11/37) and those
with IDDM (5/15). The rate of moderate/severe steatosis was
6/135 (4.4%) in normal weight, nondiabetic patients, 39/249
(15.6%) in overweight nondiabetics (𝑃 = 0.001), 0/12 in
normal weight diabetics, and 15/39 (38.5%) in overweight
diabetics (𝑃 < 0.001).
Elevated preoperative transaminase levels were noted in
18 of 60 patients (30%) with moderate/severe steatosis and
61 of 369 patients (16.5%) with steatosis <33% (𝑃 = 0.019).
The sensitivity and specificity of elevated transaminases for
predicting the presence of moderate or severe steatosis were
30% and 83%, respectively.
Multivariate analysis revealed that elevated BMI ≥
25 kg/m2 (𝑃 = 0.001) and the presence of diabetes (𝑃 =
0.018) were significantly associated with moderate/severe
hepatic steatosis (Table 1). BMI ≥ 25 kg/m2 increased the
risk by a factor of 2.97 and diabetes increased the risk by a
factor of 2.69. Among diabetic patients insulin dependence
increased the risk of moderate/severe steatosis by a factor of
4.31 (𝑃 = 0.037). However, BMI ≥ 30 kg/m did not increase
the risk of moderate/severe steatosis compared to BMI of 25–
29.9 (𝑃 = 0.144). Raised preoperative transaminase levels
also increased the risk of moderate/severe steatosis by a
factor of 3.82 (𝑃 < 0.001), and raised preoperative alkaline
phosphatase concentrations decreased the risk by a factor of
0.15 (𝑃 = 0.001). Hepatic steatosis was not associated with
liver-directed chemotherapy or other biochemical markers
of liver dysfunction (preoperative hypoalbuminemia and
hyperbilirubinemia).
During the study period 94 patients developed a
major postoperative complication. Twenty-three patients
died within 90 days of surgery (4.6%) and 71 patients who
survived beyond 90 days suffered a major complication
(14.1%).Themost common cause ofmortality was liver failure
(nine patients).
Of patients who developed Grade IV complications
34/64 (53.1%) developed PHLF and 31/64 developed renal
failure (48.4%). Of the 34 patients who developed PHLF
29 had undergone major liver resection. Twenty-three
patients developed bile leaks, and seven required relaparo-
tomy/relaparoscopy. Multivariate analysis revealed that older
age, male gender, hypoalbuminaemia, synchronous bowel
procedures, number of segments resected, and blood trans-
fusion were independent risk factors for major postoperative
complications (Table 2). There was no association between
NIDDM, BMI, or degree of hepatic steatosis and major
postoperative complications. IDDM more than trebled the
risk of major complication compared to nondiabetics and
those with NIDDM. The complications in these groups
are shown in Table 3. The greatest risk however occurred
when liver resection was undertaken in conjunction with
a synchronous bowel procedure, which increased the risk
of major complication almost six times that of a liver-only
resection. Ten of 23 patients developed major postoperative
complications, six of whom had colonic resections (three
right sided and three left sided), three had small bowel
procedures, and one had a gastric resection.
In the 299 patients who underwent major resection,
there was no significant difference in the proportion of
patients with steatosis≥33% between patients who did (10/64,
15.6%) or did not (23/201, 11.4%) developmajor complications
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(𝑃 = 0.388). Similarly there was no significant difference
in the proportion of patients with steatosis ≥33% between
patients who did (4/22, 15.6%) or did not (29/243, 11.9%)
develop PHLF (𝑃 = 0.495).
4. Discussion
The principal finding of this study is that although diabetes
mellitus and higher BMI are risk factors for steatosis in
patients undergoing liver resection, the majority of cases of
steatosis occur in nondiabetic patients with mildly elevated
BMI (25–30). Secondly, steatosis and elevated BMI are
not associated with major complications after liver resec-
tion, and diabetes is a risk factor for these complications
only if patients are insulin dependent. Other predictors of
major complications are older age, male gender, preoperative
hypoalbuminaemia, synchronous bowel procedures, number
of segments resected, and requirement for blood transfusion.
The 90-day mortality (4.6%) and morbidity (14.7%) rate
are similar to published series [4, 18, 38], although other series
have included minor (Grade I and II) complications [39–41].
Composite outcomes similar to the one used in this study
have been used previously in studies evaluating outcomes
following gastrointestinal surgery [42, 43]. The present study
confirms the association between hepatic steatosis and BMI
[44].Whilst the rate ofmoderate/severe steatosis was greatest
in overweight diabetic patients (38.5%), it also occurred in
patients of normal weight without diabetes (4.4%). This sug-
gests that other risk factorsmay be involved in the aetiology of
the disease. Undernutrition [17], impaired glucose tolerance
[45], and genetic factors [46] have also been implicated in the
development of NAFLD. Alcohol consumption is an unlikely
cause of steatosis in this series as all patients are asked to
abstain from alcohol consumption prior to surgery, although
compliance with this instruction has not been assessed.
Elevated transaminase levels are associated with hepatic
steatosis, but the sensitivity of abnormal transaminases in
detecting moderate or severe NAFLD is poor, as 70% of
these patients had normal transaminase levels. This is in
keeping with other studies [47]. Interestingly, raised preop-
erative alkaline phosphatase concentration was associated
with decreased incidence of steatosis. Elevated alkaline phos-
phatase may be found in cases of biliary obstruction, and
of the 119 patients with this finding 16.8% had cholangio-
carcinomas compared to only 2.9% of the 380 patients with
normal alkaline phosphatase. This group is more likely to be
systemically unwell as a consequence of biliary obstruction
and to have suffered a period of anorexia and weight loss,
which may affect the degree of hepatic steatosis.
Preoperative chemotherapy was not shown to be asso-
ciated with steatosis. Studies have shown an association
between steatohepatitis and irinotecan therapy [18], which
was rarely used in this series. In addition the policy in this
unit is to use only four cycles of chemotherapy and to allow
a period of recovery before undertaking liver resection, to
allow resolution of hepatotoxicity.
Previous studies have shown that steatosis increases the
risk of PHLF [8, 21]. The rate of PHLF in this series was low
(6.7%) and occurred in 6.6% patients with moderate/severe
steatosis and 6.1% of the patients with none/mild steatosis.
The majority of cases of PHLF followed major liver resection
(29/34). It is possible that there is an independent association
between steatosis and PHLF, which is not revealed in this
study which uses a composite outcome including other
complications in the multivariate analysis. Steatosis may be
a risk factor for liver failure in patients undergoing extended
hepatectomy, although not in major hepatectomy in this
series, where the risk of this complication is greatest. Previous
studies have recommended liver biopsy to investigate the
presence of steatosis prior to resection [48, 49]. The current
study suggests that the risk of this investigation is not justified
due to the lack of effect of steatosis on outcome.
The rate of bile leak requiring intervention (4.6%) was
not affected by the degree of hepatic steatosis suggesting that
hepatic steatosis does not make parenchymal division more
difficult to perform.
Elevated BMI was not associated with major complica-
tions in this series, although it may be associated with more
minor complications such as wound infection which has not
been explored in this study.
Diabetes was an independent risk factor for compli-
cations after liver surgery which confirms the findings of
previous studies [5, 50–52], although identification of insulin
dependence as the major risk factor is a novel finding. Whilst
there was no significant difference in the risk of major com-
plications between nondiabetic patients and those with non-
insulin dependent diabetes, the risk of complications was
more than trebled in those with insulin dependent diabetes.
This finding reflects the multisystem nature of diabetic end-
organ damage. Diabetic nephropathy is amajor cause of renal
dysfunction [53] and was the most common complication
in patients with IDDM. Renal dysfunction was also twice as
common amongst patients with IDDM compared to those
with NIDDM.
Older age, male gender, preoperative hypoalbuminaemia,
number of liver segments resected, and requirement for
blood transfusion have all been previously identified as risk
factors for postoperative complications [38]. The finding that
performing synchronous bowel procedures is associated with
worse outcome is similar to that of a previous study which
found that the risk of a major complication was 20.4% after
a synchronous colonic resection compared to 14.9% after a
liver-only resection [54]. Although a recent systematic review
suggested no difference in terms of overall morbidity or
mortality between synchronous and staged resections [55]
the results of the present study reveal the risk of developing a
major complication after a synchronous bowel procedure was
almost six times that of a liver-only resection. It should also
be noted that the synchronous procedures included a gastric
resection and Whipple’s procedure which may pose different
risks to colonic resections. Most of the increased risk in this
context relates to leaks from enteric anastomoses.
5. Conclusions
The results of this study allow clinicians to advise patients
regarding the risks of liver resection and to place them
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in context. In particular, liver surgery in the presence of
steatosis, elevated BMI, and NIDDM does not lead to greatly
increased operative risk. While insulin dependence is a
significant risk factor for complications after liver surgery, the
major risk factors in this series related to technical details of
the operation, particularly the performance of simultaneous
bowel procedures.
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